Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2024-04-09
2024-06-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Interleukin-6 Secretion in Adipose Tissue Following Sprint Exercise
NCT04566354
MyoGene: Effects of Acute Exercise on (Myokine) Gene Expression in Human Skeletal Muscle
NCT01316731
Role of Interleukin-6 in Exercise
NCT01073826
Myokine Identification Following Acute Exercise
NCT06223035
Profile and Regulatory Network of Exercise in Improving Metabolic Phenotypes of Patients with Prediabetes
NCT06633575
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Saline infusion
exercise
acute exercise bout
Tocilizumab
IL-6 receptor antibody infusion (8 mg/kg body weight, max 800 mg)
exercise
acute exercise bout
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
exercise
acute exercise bout
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Maximum age: 45 years
* Minimum BMI: 18
* Maximum BMI: 25
* Sex: Male
* Healthy (based on screening)
* Stable body weight for 6 months
* VO2max (mL/kg/min) ≥ 50
Exclusion Criteria
* Thyroid disease
* Heart disease
* Inflammatory diseases
* Current infection
* Liver disease (transaminases more than 2x upper normal range)
* Kidney disease (creatinine more than1.5 mg/dl)
* Known immunosuppressive disease
* Corticosteroid use
* Regular NSAID or paracetamol usage
* Aspirin use more than 100 mg/d
* History of carcinoma
* History of tuberculosis
* Anemia (hematocrit less than 33%)
* WBC less than 1 x 10\^3
* Platelets less than 100 x 10\^3
* Bleeding disorders
* Obstructive pulmonary disease
* Femoral hernia
* Vascular prosthesis
* Vascular thrombosis
* Previous nerve damage
* Many previous femoral catheter installations
18 Years
45 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Helga Ellingsgaard
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Helga Ellingsgaard
Principle Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Helga Ellingsgaard, PhD
Role: PRINCIPAL_INVESTIGATOR
Rigshospitalet, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rigshospitalet
Copenhagen, Capital Region, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-23069670
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.